Physicians

Departments / Divisions

• Pediatrics / Pediatrics-Hematology/Oncology
• Surgery / Neurosurgery

Address
DUMC 102382
Durham, NC 27710

Appointment Telephone
919-668-6288

Office Telephone
919-668-6288

Fax Telephone
919-668-2485

Training

• MRCP (UK), Stanley Medical College (India), 1982

Residency

• Pediatrics, Lebonheur Children's Medical Center (Tennessee), 1992-1993

Fellowship

• Pediatric Hematology/Oncology, St. Jude Children's Research Hospital (Tennessee), 1991-1992
• Pediatric Hematology/Oncology, Memorial Sloan-Kettering Cancer Center (New York), 1996-1999

Other Training

• Member (Pediatrics), Royal College of Physicians (England), 1988

Clinical Interests
Developing innovative phase 1 and 2 trials in the treatment of children with recurrent brain tumors

Research Interests
Dr. Gururangan is a member of the Duke University Medical Center Pediatric Neuro-Oncology program. His current research interest focuses on finding novel chemotherapeutic strategies for the treatment of children and young adults with brain tumors. Since beginning his tenure at the Brain Tumor Center at Duke, he has written seven clinical protocols. These protocols have incorporated some of the important laboratory findings obtained from the laboratory of Dr. Henry Friedman. These protocols are designed to improve survival of children and young adults with brain stem gliomas and other malignant brain tumors. These protocols will be administered locally and in other prominent brain tumor centers around the country that are part of the Pediatric Brain Tumor Consortium.  Dr. Gururangan is the subsite principal investigator for another multi-institutional phase III study of upfront radiation therapy followed dose intensive chemotherapy plus stem cell rescue in children with newly diagnosed medulloblastoma, other PNETs, and ATRT. This study originates at St. Jude Children's Research Hospital, Memphis, TN. The Preston Robert Tisch Brain Tumor Center also has a broad-based agreement with the same institution for broad-based collaboration for clinical trials that originate at Duke or St. Jude Children's Hospital. Dr. Gururangan is the Principal Investigator for Duke in the Pediatric Brain Tumor Consortium sponsored by the National Cancer Institute. He has completed and published two phase I studies through this consortium involving novel alkylating agents in children with recurrent brain tumors. He is currently the chair of an ongoing large phase II study of Bevacizumab plus irinotecan in children with recurrent malignant glioma, diffuse brain stem glioma, medulloblastoma, ependymoma, and low grade gliomas that is also managed through the consortium. Dr. Gururangan is a member of the Duke Brain Tumor SPORE program and the Children's Oncology Group.  Also, through his close ties with an elite group of basic and translational scientists at Duke, he is involved in developing immunology based therapies for children with brain tumors. As a member of these mutliple intramural and extramural groups he is in a strategic position to evaluate novel therapeutic modalities in patients with brain tumors and conduct other  phase I and II clinical trials in children with brain tumors.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Abbott Laboratories
• Boehringer Ingelheim

Representative Publications
Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ. Phase I Trial of MK-0752 in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2011 Sep 10;29(26):3529-34. (2011) Abstract

Peters KB, Cummings TJ, Gururangan S. Transformation of juvenile pilocytic astrocytoma to anaplastic pilocytic astrocytoma in patients with neurofibromatosis type I. J Pediatr Hematol Oncol. 2011 Jul;33(5):e198-201. (2011) Abstract

Rajagopal MU, Hathout Y, MacDonald TJ, Kieran MW, Gururangan S, Blaney SM, Phillips P, Packer R, Gordish-Dressman H, Rood BR. Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study. Proteomics. 2011 Mar;11(5):935-43. (2011) Abstract

Dunkel IJ, Jubran RF, Gururangan S, Chantada GL, Finlay JL, Goldman S, Khakoo Y, O'Brien JM, Orjuela M, Rodriguez-Galindo C, Souweidane MM, Abramson DH. Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatr Blood Cancer. 2010 Mar;54(3):384-7. (2010) Abstract

Fangusaro J, Massimino M, Rutkowski S, Gururangan S. Non-cerebellar primitive neuroectodermal tumors (PNET): summary of the Milan consensus and state of the art workshop on marrow ablative chemotherapy with hematopoietic cell rescue for malignant brain tumors of childhood and adolescents. Pediatr Blood Cancer. 2010 Apr;54(4):638-40. (2010) Abstract

Geyer JR, Stewart CF, Kocak M, Broniscer A, Phillips P, Douglas JG, Blaney SM, Packer RJ, Gururangan S, Banerjee A, Kieran MW, Kun LE, Gilbertson RJ, Boyett JM. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010 Dec;46(18):3287-93. (2010) Abstract

Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010 Jun 20;28(18):3069-75. (2010) Abstract

Fouladi M, Gururangan S, Moghrabi A, Phillips P, Gronewold L, Wallace D, Sanford RA, Gajjar A, Kun LE, Heideman R. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer. 2009 Jul 15;115(14):3243-53. (2009) Abstract

Gururangan S. Late effects of chemotherapy. Cancer Treat Res. 2009;150:43-65. (2009) Abstract

Bonner MJ, Hardy KK, Willard VW, Anthony KK, Hood M, Gururangan S. Social functioning and facial expression recognition in survivors of pediatric brain tumors. J Pediatr Psychol. 2008 Nov-Dec;33(10):1142-52. (2008) Abstract

Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, Gronewold L, Stewart CF, Wallace D, Broniscer A, Hale GA, Kasow KA, Merchant TE, Morris B, Krasin M, Kun LE, Boyett JM, Gajjar A. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008 Aug 1;26(22):3749-55. (2008) Abstract

Gururangan S, Frankel W, Broaddus R, Clendenning M, Senter L, McDonald M, Eastwood J, Reardon D, Vredenburgh J, Quinn J, Friedman HS. Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncol. 2008 Feb;10(1):93-7. (2008) Abstract

Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, Rich JN, Quinn JA, Vredenburgh JJ, Desjardins A, McLendon RE, Fuchs H, Kurtzberg J, Friedman HS. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol. 2008 Oct;10(5):745-51. (2008) Abstract

Gururangan S, Turner CD, Stewart CF, O'Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res. 2008 Feb 15;14(4):1124-30. (2008) Abstract

Hardy KK, Bonner MJ, Willard VW, Watral MA, Gururangan S. Hydrocephalus as a possible additional contributor to cognitive outcome in survivors of pediatric medulloblastoma. Psychooncology. 2008 Nov;17(11):1157-61. (2008) Abstract

Keir ST, Morton CL, Billups C, Smith MA, Houghton PJ, Gururangan S. Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Sep;51(3):439-41. (2008) Abstract

Serafini S, Gururangan S, Friedman A, Haglund M. Identification of distinct and overlapping cortical areas for bilingual naming and reading using cortical stimulation. Case report. J Neurosurg Pediatr. 2008 Mar;1(3):247-54. (2008) Abstract

Walker JA, Dixon N, Gururangan S, Thornburg C. Perioperative factor IX replacement for surgical resection of a suprasellar astrocytoma in a child with severe haemophilia B. Haemophilia. 2008 Mar;14(2):387-9. (2008) Abstract

Bai F, Minkin P, Fraga CH, O'Shaughnessy MA, Gururangan S, Stewart CF. Determination of Cloretazine (VNP40101M) and its active metabolite (VNP4090CE) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 15;853(1-2):97-104. (2007) Abstract

Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007 Nov 15;110(10):3526-31. (2007) Abstract

Broniscer A, Gururangan S, MacDonald TJ, Goldman S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY, Kun LE, Boyett JM, Gajjar A. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6712-8. (2007) Abstract

Gururangan S, Fisher MJ, Allen JC, Herndon JE 2nd, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007 Apr;9(2):161-8. (2007) Abstract

Gururangan S. Advances in the diagnosis and treatment of malignant childhood brain tumors. Clin Adv Hematol Oncol. 2007 Feb;5(2):120-2. (2007) Abstract

Jackson EM, Shaikh TH, Gururangan S, Jones MC, Malkin D, Nikkel SM, Zuppan CW, Wainwright LM, Zhang F, Biegel JA. High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor. Hum Genet. 2007 Sep;122(2):117-27. (2007) Abstract

Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20;25(21):3137-43. (2007) Abstract

Gururangan S, McLaughlin CA, Brashears J, Watral MA, Provenzale J, Coleman RE, Halperin EC, Quinn J, Reardon D, Vredenburgh J, Friedman A, Friedman HS. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol. 2006 Apr;77(2):207-12. (2006) Abstract

Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res. 2006 Mar 1;12(5):1540-6. (2006) Abstract

Pekala JS, Gururangan S, Provenzale JM, Mukundan S Jr. Central nervous system extraosseous Ewing sarcoma: radiologic manifestations of this newly defined pathologic entity. AJNR Am J Neuroradiol. 2006 Mar;27(3):580-3. (2006) Abstract

Mazur MA, Gururangan S, Bridge JA, Cummings TJ, Mukundan S, Fuchs H, Larrier N, Halperin EC. Intracranial Ewing sarcoma. Pediatr Blood Cancer. 2005 Nov;45(6):850-6. (2005) Abstract

Gururangan S, Friedman HS. Recent advances in the treatment of pediatric brain tumors. Oncology (Williston Park). 2004 Nov;18(13):1649-61; discussion 1662, 1665-6, 1668. (2004) Abstract

Gururangan S, Hwang E, Herndon JE 2nd, Fuchs H, George T, Coleman RE. [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery. 2004 Dec;55(6):1280-8; discussion 1288-9. (2004) Abstract

Mulhern RK, Khan RB, Kaplan S, Helton S, Christensen R, Bonner M, Brown R, Xiong X, Wu S, Gururangan S, Reddick WE. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol. 2004 Dec 1;22(23):4795-803. (2004) Abstract

Provenzale JM, Gururangan S, Klintworth G. Trilateral retinoblastoma: clinical and radiologic progression. AJR Am J Roentgenol. 2004 Aug;183(2):505-11. (2004) Abstract

Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J 2nd, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenbergh J, Martin PL. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol. 2003 Jun 1;21(11):2187-91. (2003) Abstract

Gururangan S, Cavazos CM, Ashley D, Herndon JE 2nd, Bruggers CS, Moghrabi A, Scarcella DL, Watral M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002 Jul 1;20(13):2951-8. (2002) Abstract

Gururangan S, Friedman HS. Innovations in design and delivery of chemotherapy for brain tumors. Neuroimaging Clin N Am. 2002 Nov;12(4):583-97. (2002) Abstract

Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-oncol. 2002 Apr;4(2):102-8. (2002) Abstract

Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncol. 2001 Oct;3(4):246-50. (2001) Abstract

Gururangan S, Gardner S, and Finlay JL. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for malignant tumors of the central nervous system. Clinical Bone Marrow and Stem Cell Transplantation, 2nd edition, Kerry Atkinson ed., Cambridge University Press, (in press 2000) (2000)

Gururangan S, Sposto R, Cairo MS, Meadows AT, Finlay JL. Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children's Cancer Group study. J Clin Oncol. 2000 May;18(10):2017-25. (2000) Abstract

Gururangan S, Dunkel IJ, Goldman S, Garvin J, Rosenblum M, Boyett J, and Finlay J. Myeloablative chemotherapy followed by autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998; 16 (7): 2486-2493 (1998)

Gururangan S, Marina NM, Luo X, Parham DM, Tzen CY, Greenwald CA, Rao BN, Kun LE, Meyer WH. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy. J Pediatr Hematol Oncol. 1998 Jan-Feb;20(1):55-61. (1998) Abstract

Gururangan S, McFarland JG, Cines DB, Skupski D, Bussel JB. BRa (HPA-5b) incompatibility may cause thrombocytopenia in neonates of mothers with immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 1998 May-Jun;20(3):202-6. (1998) Abstract

Gururangan S, Heideman RL, Kovnar EH, Sanford RA, Kun LE. Peritoneal metastases in two patients with pineoblastoma and ventriculo-peritoneal shunts. Med Pediatr Oncol. 1994;22(6):417-20. (1994) Abstract

Gururangan S, Bowman LC, Parham DM, Wilimas JA, Rao B, Pratt CB, Douglass EC. Primary extracranial rhabdoid tumors. Clinicopathologic features and response to ifosfamide. Cancer. 1993 Apr 15;71(8):2653-9. (1993) Abstract